Jonathan Diamond, MD
Nephrology · Harrisburg, PANPI 1578539433
Payments from drug & device makers
Across 996 payments — averaging $249.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mallinckrodt Hospital Products Inc.$105K
- Bayer$87K
- Mallinckrodt Enterprises LLC$33K
- Akebia Therapeutics Inc$9K
- AstraZeneca$3K
- Amgen$1K
- plus $10K from 25 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mallinckrodt Hospital Products Inc. | 160 | $105,494 |
| Bayer | 90 | $87,220 |
| Mallinckrodt Enterprises LLC | 69 | $33,224 |
| Akebia Therapeutics Inc | 93 | $8,648 |
| AstraZeneca(2 entities) | 80 | $3,006 |
| Amgen(2 entities) | 44 | $1,311 |
| Vifor Pharma, Inc. | 52 | $1,105 |
| ANI Pharmaceuticals, Inc. | 84 | $1,083 |
| OPKO Pharmaceuticals, LLC | 45 | $1,030 |
| Otsuka America Pharmaceutical, Inc. | 39 | $993 |
| Travere Therapeutics, Inc. | 17 | $815 |
| Fresenius USA Marketing, Inc. | 29 | $735 |
| Ardelyx, Inc. | 54 | $718 |
| GSK | 20 | $607 |
| Calliditas Therapeutics US Inc. | 33 | $538 |
| Aurinia Pharma U.S., Inc. | 24 | $527 |
| Daiichi Sankyo Inc. | 15 | $449 |
| Novo Nordisk | 3 | $268 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 12 | $266 |
| Boehringer Ingelheim | 9 | $198 |
| Scpharmaceuticals Inc. | 4 | $182 |
| Novartis | 7 | $159 |
| E.r. Squibb & Sons, L.L.C. | 1 | $104 |
| Sanofi | 2 | $101 |
| Lilly USA, LLC | 3 | $53 |
| Alnylam Pharmaceuticals Inc. | 2 | $37 |
| Tersera Therapeutics LLC | 1 | $32 |
| Apellis Pharmaceuticals, Inc. | 1 | $26 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $24 |
| Ultragenyx Pharmaceutical Inc. | 1 | $21 |
| Baxter Healthcare | 1 | $13 |
How this compares
$248,986 in reported general payments places this provider in the 95th percentile of 586 nephrology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other nephrology in Harrisburg
- Manpreet SinghHarrisburg$125K
- Katalin SusztakPhiladelphia$4.8M
- Debbie Cohen SteinPhiladelphia$2.8M
- Nelson KopytAllentown$2.1M
- Iris LeePhiladelphia$1.9M
- Abdallahsassine GearaPhiladelphia$1.2M
- Alexander ChangDanville$1000K
- Gaia MuallemPhiladelphia$942K
- Chike OkechukwuUpland$875K
- Christopher GislerPittsburgh$757K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.